Oxford Asset Management’s ADMA Biologics ADMA Stock Holding History

Oxford Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-121,741	Closed	-$1.1M	–	371
2026 Q1	$1.1M	Buy	+121,741	New	+$1.92M	0.44%	39
2025 Q1	–	Sell	-13,420	Closed	-$230K	–	472
2024 Q4	$230K	Buy	+13,420	New	+$252K	0.1%	320
2024 Q3	–	Sell	-12,374	Closed	-$138K	–	302
2024 Q2	$138K	Buy	+12,374	New	+$104K	0.13%	225
2024 Q1	–	Sell	-18,330	Closed	-$82.9K	–	259
2023 Q4	$82.9K	Buy	+18,330	New	+$67.8K	0.12%	167

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Oxford Asset Management's ADMA Position: Q2 2026 in Review

Oxford Asset Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 121,741 shares — an estimated $1.1M sold.

Oxford Asset Management first reported a position in ADMA in Q4 2023 and held it in 4 quarters. The position peaked at $1.1M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Oxford Asset Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Oxford Asset Management sold 121,741 ADMA Biologics shares in Q2 2026, an estimated $1.1M.
Oxford Asset Management first reported a position in ADMA Biologics in Q4 2023 and held it in 4 quarters.
Oxford Asset Management's ADMA Biologics position peaked at $1.1M in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.